Navigation Links
Blood Pressure Management Changed on Global Level with OSTAR's 3SI Interpretive Blood Pressure Algorithm
Date:10/24/2013

VANCOUVER, Wash., Oct. 24, 2013 /PRNewswire/ -- OSTAR Healthcare Technology, a Washington based medical device company, announced the North American launch of its revolutionary 3SI (3 simultaneous interpretations) Advanced Diagnostic Blood Pressure Algorithm. According to Doug Hemenway, President and CEO, "This North American launch of OSTAR 3SI algorithm and the following product releases to come, set the scene for a change in the overall role of blood pressure measurement globally. Furthermore they are vital steps in OSTAR's commitment to improving patient outcomes while avoiding unnecessary costs, in lockstep with current federal imperatives of Patient Privacy & Accountable Care Act (PPACA)."

(Logo: http://photos.prnewswire.com/prnh/20131024/PH03445LOGO

OSTAR – 3SI Interpretive Blood Pressure Monitoring Algorithm is the intelligent heart of the entire suite of OSTAR products, soon to be released. This unique algorithm interprets and evaluates the entire blood pressure measurement, providing meaningful early warning alerts of possible emerging Arrhythmias, Valvular and Coronary Arterial conditions to the clinical staff and patient. It is envisaged that this unique patented technology will change the relevance of the traditional automated blood pressure measurement, from that of an interesting trend measurement to a necessary useful predictive indicator of impending valvular and coronary heart disease or cardiac arrest. The 3SI algorithm will be available in all OSTAR products with a view to make it available for OEM arrangements if customer demand dictates.  The OSTAR 3SI interpretive algorithm is a natural progression, based on customer driven demand and the ongoing commitment to solving heart disease while presenting a cohesive predictive tool to the global clinical and patient world. "Over the long run this form of automated blood pressure algorithm could have an even greater impact than advent interpretive ECG algorithms or AED defibrillators," as stated by Paul A Markham President of V3 Healthcare Strategies. The result is reduced cost to healthcare systems and ultimately, to the American healthcare consumer.

About OSTAR Healthcare Technology

Based in Vancouver, Washington, OSTAR's Healthcare Technology's Suite of unique suite of Next Generation Patient Monitoring solutions brings forth superiority over conventional product's specification, quality and lower price; we challenge entire global hospitals blood pressure and oximeter measuring instruments. OSTAR services the academic teaching, acute, ambulatory and home care marketplace.

CONTACT INFORMATION:                                                            
Doug Hemenway
OSTAR Healthcare Technology
Email
www.ostar.us
Toll free: 800-654-2548       Fax: 360-883-6086

Read more news from OSTAR


'/>"/>
SOURCE OSTAR
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Haemonetics Signs Definitive Agreement to Acquire Pall Corporations Blood Collection, Filtration and Processing Product Lines For $551 Million
2. National Jewish Health, the Nations Premier Respiratory Hospital, Announces Lung Cancer Screening Trial Using Blood Test and CT
3. Blood Disorders: European Hematologists Gather in Amsterdam, June 14-17, 2012
4. Failure to Take Medicine Linked to Unnecessary Hospital Visits, Especially for Medicare Patients Taking High Blood Pressure or High Cholesterol Medications
5. NuMe Health Completes $1.5 Million Series A Financing To Advance Its First Cobiotic™ Aimed At Helping Prediabetics Maintain Healthy Blood Glucose Levels
6. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
7. Glooko Launches the Glooko™ IR Adapter to Give ACCU-CHEK® Blood Glucose Meter Customers Access to the Glooko Logbook Solution
8. OICR funds Fluorinov Pharma Inc. to further develop its novel drug for the treatment of blood cancers
9. Spot On Sciences Awarded $1 Million DARPA Grant to Develop a Blood Sample Collection Device
10. Diabetes Care Devices in Emerging Countries (China, India, Brazil) to 2017 - Greater Awareness is Increasing Demand for Self-Monitoring of Blood Glucose (SMBG) in the Home Care Segment
11. Global Growth Factors (Blood And Tissue) Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... 12, 2017   Divoti USA will engrave ... the standard of the latest FDA requirements, which stipulates new criteria ... Anyone in need of Medical ID jewelry such as Medical ID ... are engraved in terms of the new FDA requirements . ... Divoti offers this dark mark ...
(Date:10/11/2017)... 2017  Caris Life Sciences ® , a leading ... of precision medicine, today announced that St. Jude Medical ... Alliance™ (POA) as its 17 th member. Through ... Crosson Cancer Institute will help develop standards of care ... profiling, making cancer treatment more precise and effective. ...
(Date:10/10/2017)...  NDS received FDA 510(k) clearance in May 2017 for its ... specifically designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... to support the improvement of patient outcomes, procedural efficiency, and the ... ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... N.J. (PRWEB) , ... October 13, 2017 , ... The ... Holly Day Market. Featuring a collection of specialty vendors and unique items from across ... personalized and quality-focused health and wellness services offered by the VNA. The boutique ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... DevOps and Agile Software Development, has been awarded a contract by the Center ... Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in ...
(Date:10/12/2017)... LA (PRWEB) , ... October 12, 2017 , ... Planet ... in the U.S., announced today its plans to open a flagship location in Covington, ... occupy the former Rooms To Go store next to Office Depot in the Holiday ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: , ... to enable prevention of a major side effect of chemotherapy in children. Cisplatin ... patients. For cisplatin, hearing loss is FDA listed on-label as a dose limiting ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... been named one of Michigan’s 2017 Best and Brightest in Wellness® by Best ... in Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. to 2 ...
Breaking Medicine News(10 mins):